Sequenom Completes $62M Public Offering | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom announced after the close of the market on Wednesday that it has completed its public offering of 14.95 million shares of its common stock at $4.15 per share, raising about $62 million in gross proceeds.

The number of shares includes 1.95 million shares sold pursuant to the full exercise of an over-allotment option granted to its underwriters. Jefferies acted as sole book-running manager for the offering. Oppenheimer and William Blair were co-managers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.